Overview

Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

Status:
Terminated
Trial end date:
2021-04-07
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy, safety, tolerability, and pharmacokinetics of once daily SJX-653 in postmenopausal women with moderate to severe VMS.
Phase:
Phase 2
Details
Lead Sponsor:
Sojournix, Inc.